This study aims to understand how HIV interacts with your body when you temporarily stop taking your HIV medications (antiretroviral therapy or ART). You would pause your ART, and researchers would closely monitor your health and virus levels, often two to three times a week. Most participants will restart ART within three weeks, even if their virus levels haven't gone up. The main goals are to see if you develop acute retroviral syndrome, if your virus levels go back down after restarting ART, and if your CD4+ T-cell count (a measure of immune health) declines. To join, you must be at least 18 years old, have documented HIV, have been on ART for at least 12 months with undetectable virus levels, and have a CD4+ T-cell count above 350.

Study design

This is an interventional study with a planned enrollment of 40 participants. It involves a treatment interruption arm where participants will pause their ART.

What's involved

You will interrupt your ART and have intensive studies performed two to three times per week. Most will resume therapy within three weeks, or once the virus is detectable.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for acute retroviral syndrome for up to 6 months, failure to re-suppress for up to 12 months, and CD4+ T cell decline for up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.